| CAN | acetonitrile |
| ADT | androgen deprivation therapy |
| AF-2 | activation function-2 |
| AR | androgen receptor |
| ARE | androgen response element |
| Boc | tert-butoxycarbonyl |
| CDCl3 | deuterated chloroform |
| CHC | α-cyano-4-hydroxycinnamic acid |
| DIEA | N,N-diisopropylethylamine |
| DMF | N,N-dimethylformamide |
| DCM | dichloromethane |
| DHT | 5α-dihydrotestosterone |
| DMSO-d6 | deuterated dimethyl sulfoxide |
| EtOAc | ethyl acetate |
| ESI | electrospray ionization |
| Fmoc | 9-fluorenylmethoxycarbonyl |
| HATU | 2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate |
| HOAt | 1-hydroxy-7-azabenzotriazole |
| HPLC | high performance liquid chromatography |
| IC50 | half-maximal inhibitory concentration |
| HRMS | high resolution mass spectrometry |
| LBD | ligand-binding domain |
| LNCaP | lymph node carcinoma of the prostate |
| MALDI-TOF MS | matrix-assisted laser desorption/ionization time-of flight mass spectrometry |
| MTT | 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide |
| NMR | nuclear magnetic resonance |
| PCa | prostate cancer |
| PELP1 | proline-, glutamic acid-and leucine-rich-protein-1 |
| PyBOP | (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate |
| TFA | trifluoroacetic acid |
| THF | tetrahydrofuran |
| TLC | thin-layer chromatography |